Clinical Trial Detail

NCT ID NCT04335292
Title Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Mark Vincent
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Osimertinib

Age Groups: senior adult

Additional content available in CKB BOOST